Calcium phosphate/cholecalciferol

Selected Citracal gummies supply calcium as tricalcium phosphate plus cholecalciferol to support calcium intake and bone health. They carry Supplement Facts rather than prescription Drug Facts and the manufacturer disclaims disease diagnosis/treatment/prevention approval. Do not confuse the brand’s name with calcium citrate: this selected gummy uses phosphate.

Use supplements to address an assessed dietary shortfall or clinician-directed need. A fixed calcium/vitamin D supplement is not a universal treatment for osteoporosis, hypocalcemia, diagnosed vitamin D deficiency or CKD mineral/bone disorder. Product strengths, age directions and phosphorus content matter; no injectable calcium-phosphate or prescription vitamin D protocol is supplied.

Adults and children twelve years and older fully chew two gummies twice daily, with or without food, or as advised by the health professional. One two-gummy serving supplies calcium 500 mg, vitamin D3 25 mcg (1,000 IU) and phosphorus 225 mg. The full labeled daily four-gummy amount therefore supplies 1,000 mg calcium, 50 mcg (2,000 IU) D3 and 450 mg phosphorus, before food/other products. Do not exceed recommended intake or apply these gummy instructions to another tablet.

Dietary reference values are TOTAL daily intake goals, not automatic supplement doses. Calcium goals: 1,300 mg at ages 9–18; 1,000 mg for ages 19–50 and men 51–70; 1,200 mg for women 51–70 and all adults over seventy. Vitamin D goals: 15 mcg (600 IU) at ages 1–70, 20 mcg (800 IU) over seventy; infants use separate 10 mcg (400 IU) adequate intake and an age-appropriate product. Assess food first; the selected gummy is not for under-twelves.

Calcium total-intake UL is 3,000 mg/day for ages 9–18, 2,500 mg for ages 19–50 and 2,000 mg above fifty; vitamin D UL is 100 mcg (4,000 IU) from age nine. These limits are not goals or proof of safety with kidney disease, high calcium or interacting medicines. Calcium absorption is more efficient at individual amounts ≤ 500 mg, supporting divided intake rather than a single large unsupervised dose.

The selected panel has no validated renal/hepatic reduction or dialysis dose. Medical conditions, pregnancy, breastfeeding and medicines require professional advice. Renal disease can complicate calcium/phosphorus balance and vitamin D activation; do not convert this combination into a phosphate-binder or calcitriol regimen. Diagnosed deficiency/abnormal calcium needs individualized assessment, not automatic escalation of a supplement serving.

This supplement panel does not contain an Rx-style formal contraindication list. Avoid a product containing an ingredient to which the patient is allergic; the selected label declares wheat. Existing hypercalcemia, hypercalciuria, kidney/stone disease or disturbed mineral balance calls for clinical assessment before adding calcium/D3. Do not mistake absence of a formal list for unrestricted use.

The selected dietary-supplement panel has no FDA prescription boxed warning. It also does not confer FDA disease-treatment approval; its intake, age, allergen and medical-consultation warnings remain relevant.

Calcium supplements can cause gas, bloating or constipation. Excess calcium/D3 can produce nausea, weakness, thirst, frequent urination or renal complications. There is no controlled product-specific adverse-event frequency table for these gummies in the reviewed panel; vitamin D toxicity usually reflects excessive supplement exposure, not ordinary dietary intake.

Calcium can reduce absorption of certain medicines, including levothyroxine, quinolone antibiotics and dolutegravir. Have the pharmacist apply the specific medicine’s label and food instructions; the NIH levothyroxine example concerns calcium carbonate, so this profile does not invent a phosphate-specific tested four-hour interaction study. Dolutegravir and antibiotic rules can depend on product/food and should not be collapsed into a universal two-hour gap.

Lithium can increase calcium and combined supplementation may add risk. Thiazides reduce calcium excretion and vitamin D may add hypercalcemia risk, especially with renal impairment or hyperparathyroidism. Orlistat can reduce vitamin D absorption; corticosteroids can impair calcium absorption/vitamin D metabolism. Review duplicate calcium, phosphorus, vitamin D and active vitamin D therapy before use.

Manufacturer directions begin at twelve; under-twelves need a different assessed product, not a fraction of this gummy serving. Healthy older adults have age-specific intake goals and individual swallowing/diet/renal considerations. Reference goals do not justify automatically adding the full manufacturer dose on top of an already adequate diet.

Ask a health professional before using the selected supplement. Healthy pregnancy/lactation calcium goals are 1,300 mg/day at ages 14–18 or 1,000 mg at ages 19–50; vitamin D goal is 15 mcg (600 IU). Include prenatal and dietary intake. These are total nutritional reference amounts, not a mandate for four gummies or proof that higher-dose treatment is appropriate.

No product-specific renal/hepatic adjustment is established. Impaired kidneys can change activation and mineral handling; liver/intestinal disease can affect vitamin D metabolism or absorption. A phosphate-containing combination may not fit a prescribed phosphorus plan; clinicians must assess the exact 225 mg phosphorus per serving. It is not an automatic replacement for calcitriol or a renal phosphate binder.

Calcium contributes to bone/teeth, neuromuscular function and signaling. Vitamin D supports intestinal calcium absorption; D3 is activated first to 25-hydroxyvitamin D in liver and then principally to calcitriol in kidney. Nutritional D3 is not already-active calcitriol, and dose equivalence cannot be inferred from matching micrograms.

Calcium absorption varies with amount, diet and physiology; larger single supplement doses are less efficiently absorbed. The manufacturer gives no product-specific PK half-life or renal-clearance model. Serum calcium is tightly regulated and does not by itself measure adequacy of calcium intake. If vitamin D testing is clinically indicated, 25(OH)D is the principal status marker, not routine calcitriol measurement.

Review food, fortified products, other supplements, calcium/D3/phosphorus totals, medicines, kidney/stone history and symptoms. Clinical concerns may require calcium, renal/mineral assessment and indicated 25(OH)D testing; no universal healthy-user lab schedule or fixed target is supplied. Unexplained abnormal calcium needs diagnosis rather than simply more supplementation.

Fully chew the age-appropriate labeled serving; keep out of children’s reach and do not treat gummies as candy. Verify wheat/allergen and sugar content. Ask about medication timing, pregnancy/feeding and medical conditions; report suspected adverse effects/overdose and bring the exact bottle to assessment. Check the actual purchased package because manufacturer online facts can change.

Selected Bayer/Citracal Calcium +D3 Gummies are natural raspberry flavor with a two-gummy serving. Current linked manufacturer panel is version 001 dated September 20, 2023. This review supplies no invented NDC, tablet imprint or universal fixed package count for a dietary supplement.

Per two gummies: calcium 500 mg as tricalcium phosphate, phosphorus 225 mg and vitamin D3 25 mcg (1,000 IU). D3 conversion is 1 mcg = 40 IU. The 500 mg is elemental calcium, not 500 mg total phosphate salt. One gummy contributes half the serving nutrients arithmetically, but the labeled serving remains two gummies. Other tablets/gummies need their own verified facts.

Keep the child-resistant package out of children’s reach and follow the actual bottle’s storage/expiry instructions. The reviewed current online panel does not state a numeric storage-temperature or opening-expiry limit; no borrowed drug-label rule is supplied. Manufacturer notes color may change without altering potency/flavor.